Breaking News

Medivir, Daewoong Discontinue Hep B Alliance

September 6, 2013

MIV-210 fails to eradicate HBV

Medivir AB and Daewoong Pharmaceutical Co. Ltd. have decided to discontinue development of hepatitis B compound, MIV-210, based on a joint decision.
 
Under the collaboration Daewoong was responsible for R&D. While MIV-210 demonstrated competitive antiviral activity, like other drugs of this class, it did not completely eradicate HBV. Taking into consideration the commercial environment for HBV drugs, with the current standard of care approaching generic status, a robust cure profile is needed, which would require combination with other drugs.
 
“In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210”, said Maris Hartmanis, chief executive officer, Medivir AB.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems